Literature DB >> 28360338

Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgRKT to the List.

Calvin Yeang1, Philip L S M Gordts1, Sotirios Tsimikas2.   

Abstract

Entities:  

Keywords:  Editorials; LDL receptor; PCSK9; aortic valve stenosis; lipoprotein(a); plasminogen

Mesh：

Substances：

Year:  2017        PMID： 28360338      PMCID： PMC5470738          DOI： 10.1161/CIRCRESAHA.117.310700

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   23.213


× No keyword cloud information.
  15 in total

1.  Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a].

Authors:  William J Cain; John S Millar; Adam S Himebauch; Uwe J F Tietge; Cyrille Maugeais; David Usher; Daniel J Rader
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

Review 2.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.

Authors:  Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2017-02-14       Impact factor: 24.094

3.  Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.

Authors:  Evan A Stein; Narimon Honarpour; Scott M Wasserman; Feng Xu; Rob Scott; Frederick J Raal
Journal:  Circulation       Date:  2013-09-06       Impact factor: 29.690

4.  Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Authors:  Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-05       Impact factor: 8.311

5.  Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.

Authors:  Frederick J Raal; G Kees Hovingh; Dirk Blom; Raul D Santos; Mariko Harada-Shiba; Eric Bruckert; Patrick Couture; Handrean Soran; Gerald F Watts; Christopher Kurtz; Narimon Honarpour; Lihua Tang; Sree Kasichayanula; Scott M Wasserman; Evan A Stein
Journal:  Lancet Diabetes Endocrinol       Date:  2017-02-16       Impact factor: 32.069

6.  Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a).

Authors:  Monika Sharma; Gregory M Redpath; Michael J A Williams; Sally P A McCormick
Journal:  Circ Res       Date:  2016-12-21       Impact factor: 17.367

7.  Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice.

Authors:  S L Hofmann; D L Eaton; M S Brown; W J McConathy; J L Goldstein; R E Hammer
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

8.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Authors:  Nicholas J Viney; Julian C van Capelleveen; Richard S Geary; Shuting Xia; Joseph A Tami; Rosie Z Yu; Santica M Marcovina; Steven G Hughes; Mark J Graham; Rosanne M Crooke; Stanley T Crooke; Joseph L Witztum; Erik S Stroes; Sotirios Tsimikas
Journal:  Lancet       Date:  2016-09-21       Impact factor: 79.321

Review 9.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.

Authors:  Calvin Yeang; Michael J Wilkinson; Sotirios Tsimikas
Journal:  Curr Opin Cardiol       Date:  2016-07       Impact factor: 2.161

10.  Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.

Authors:  Gissette Reyes-Soffer; Marianna Pavlyha; Colleen Ngai; Tiffany Thomas; Stephen Holleran; Rajasekhar Ramakrishnan; Wahida Karmally; Renu Nandakumar; Nelson Fontanez; Joseph Obunike; Santica M Marcovina; Alice H Lichtenstein; Nirupa R Matthan; James Matta; Magali Maroccia; Frederic Becue; Franck Poitiers; Brian Swanson; Lisa Cowan; William J Sasiela; Howard K Surks; Henry N Ginsberg
Journal:  Circulation       Date:  2016-12-16       Impact factor: 29.690
View more
  5 in total

Review 1.  Functions of the plasminogen receptor Plg-RKT.

Authors:  Lindsey A Miles; Juliana P Vago; Lirlândia P Sousa; Robert J Parmer
Journal:  J Thromb Haemost       Date:  2020-08-19       Impact factor: 5.824

Review 2.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Authors:  Shipra Agrawal; Joshua J Zaritsky; Alessia Fornoni; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2017-11-27       Impact factor: 28.314

Review 3.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

Review 4.  NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.

Authors:  Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu
Journal:  J Am Coll Cardiol       Date:  2018-01-16       Impact factor: 24.094

5.  A methodology for predicting tissue-specific metabolic roles of receptors applied to subcutaneous adipose.

Authors:  Judith Somekh
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.